Between now and 2030, nearly 100 biologics in the US are expected to lose their exclusivity, resulting in a significant $120 billion in sales the year before expiration. This impending shift provides a substantial opportunity for the biosimilars market, which has yet to fully capitalize on its potential.
The years ahead will present valuable learning experiences for both originator and biosimilar manufacturers, ultimately shaping the future direction of the industry. As Evaluate explores the opportunities that lie ahead, it is crucial to consider factors such as defensive strategies, biosimilar contracting, and the Inflation Reduction Act (IRA) that will play a pivotal role in influencing market dynamics.
Understanding the context of the pharmaceutical, biotech, and medtech sectors is essential to navigating the evolving landscape of the biosimilars market. Medicines targeting fatty liver disease and fibrosis, for example, have the potential to mirror the remarkable growth trajectory seen in the obesity sector. While the journey to developing successful drugs for severe fatty liver disease has been lengthy, the promising outlook underscores the importance of continued innovation in this space.
Pharmaceutical companies looking to add blockbuster drugs to their portfolios must carefully assess whether to develop these drugs internally or acquire them from external sources. The allure of a potential blockbuster necessitates a strategic approach to portfolio management and acquisition decisions within the industry.
Accessing expert guides and resources, such as ‘From trials to triumph: Forecasting across the product lifecycle,’ can provide invaluable insights for those involved in pharmaceutical product management and strategy. This comprehensive playbook covers a range of topics related to forecasting, offering a roadmap for navigating the complexities of the product lifecycle.
With solid evidence supporting the efficacy of pharmacological interventions in addressing excess body weight, questions surrounding market size, pipeline value, and therapeutic potential remain at the forefront of discussions within the industry. As the landscape of rare diseases continues to evolve, specialized approaches are needed to effectively address the diverse needs of patients affected by over 7,000 rare diseases worldwide.
As we move further into 2024, the outlook for dealmaking and financial landscapes in pharma remains cautiously optimistic. The resurgence of M&A activity and IPOs signals a positive trend for investors seeking exit opportunities in the evolving market environment.
In conclusion, the biosimilars market stands poised for significant growth and development as key players navigate the changing dynamics of the pharmaceutical industry. By staying informed, leveraging data-driven insights, and embracing innovative strategies, stakeholders can capitalize on emerging opportunities and drive progress within the biosimilars sector.
